

## NOTICE

### END OF ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

The following medications:

99101433	<i>Fluvoxamine maleate</i>		1	25 mg	Caps.			
99101436	<i>Fluvoxamine maleate</i>		1	50 mg	Caps.			

are no longer authorized as alternatives for the following medications, which are once again available:

02255529	<i>ACT Fluvoxamine</i>	ActavisPhm	100	50 mg	Caps.	21.05	0.2105	
02231329	<i>Apo-Fluvoxamine</i>	Apotex	100	50 mg	Caps.	21.05	0.2105	
02236753	<i>Fluvoxamine-50</i>	Pro Doc	100	50 mg	Caps.	21.05	0.2105	
01919342	<i>Luvox</i>	BGP Pharma	30	50 mg	Caps.	25.90	0.8633	
02239953	<i>Novo-Fluvoxamine</i>	Novopfarm	100	50 mg	Caps.	21.05	0.2105	
02303345	<i>Riva-Fluvox</i>	Riva	100	50 mg	Caps.	21.05	0.2105	
			250			52.63	0.2105	

This notice has effect from 9 May 2018.

Québec, 10 April 2018

Original signed by Sylvain Périgny for :

**PAUL MARCEAU**  
President and Chief Executive Officer  
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.